
    
      This is a single-center, two cohort Phase 2 clinical trial investigating the effectiveness of
      umbralisib and ublituximab in patients with progressive CLL. Cohort A will consist of
      patients who who have progressed after receiving either a BTK inhibitor (BTKi) or BCL-2
      inhibitor.
    
  